Table 2.
Correlation between expression of NDR1 and clinical variables of GBM patients.
| Expression of NDR1 | ||||
| Variables | Low (n) | High (n) | P | χ 2 |
| Age (years) | 0.7410 | 1.250 | ||
| ≤50 | 21 | 18 | ||
| 51–60 | 23 | 19 | ||
| 61–70 | 19 | 23 | ||
| >70 | 16 | 19 | ||
| Sex | 0.5060 | 0.443 | ||
| Female | 30 | 26 | ||
| Male | 49 | 53 | ||
| Tumor size (mm) | 0.0210 | 9.773 | ||
| ≤20 | 8 | 12 | ||
| 21–40 | 21 | 36 | ||
| 41–60 | 33 | 23 | ||
| >60 | 17 | 8 | ||
| Tumor extension | 0.8330 | 0.045 | ||
| Localized at one side, not cross the midline | 65 | 66 | ||
| Invasive, cross the midline and distal metastasis | 14 | 13 | ||
| Type of surgery | 0.6820 | 0.767 | ||
| Partial resection | 18 | 14 | ||
| Gross resection | 28 | 32 | ||
| Radical resection | 33 | 33 | ||
| Radiation therapy | 0.0600 | 5.636 | ||
| Yes | 58 | 65 | ||
| No | 16 | 6 | ||
| Unknown | 5 | 8 | ||
To clarify the expression of NDR1 in GBM tissues, this study collected pathological sections of tumor samples of GBM and performed immunohistochemical staining of NDR1. It was scored according to its staining strength: negative (0 points); weakly positive (1 point); positive (2 points); strong positive (3 points).[Supplementary Figure 1A]. It was scored according to the number of positive cells stained by NDR1 IHC: <5% (0 points); 10–25% (1 point); 26–50% (2 points); 50–75% (3 points), >75% (4 points) [Supplementary Figure 1B]. Final score = number of positive cells score × staining intensity score. According to the expression scores of NDR1 in GBM tissues, they were divided into low expression group (final score ≤3 points) and high expression group (final score >3 points). Survival analysis was conducted between the two groups based on the clinical prognosis of the patients. GBM: Glioblastoma; IHC: Immunohistochemistry; NDR1: Nuclear Dbf2-related 1.